Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research
Zacks Research upgraded Rigel Pharmaceuticals (NASDAQ:RIGL) from a "strong sell" to a "hold" rating, while other analysts maintained or raised their price targets. The company recently reported strong quarterly earnings, significantly beating analyst expectations for both EPS and revenue. Institutional investors hold a substantial stake in Rigel Pharmaceuticals.
HC Wainwright Analysts Increase Earnings Estimates for RIGL
HC Wainwright analysts have increased their Q3 2026 earnings per share estimate for Rigel Pharmaceuticals (NASDAQ:RIGL) to $0.99 from $0.68, maintaining a "Buy" rating and an $85 price target. This revision follows Rigel's strong quarterly results, where EPS of $0.88 significantly beat the $0.09 consensus and revenue of $78.7 million surpassed expectations of $55.27 million. The firm also provided optimistic full-year earnings projections through 2030, while overall analyst sentiment remains mixed with an average "Hold" rating and a $59.00 consensus price target.
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $49
Piper Sandler has reiterated its Hold rating on Rigel Pharmaceuticals (RIGL.US) and increased its price target to $49. This adjustment reflects the firm's continued evaluation of the company's financial and market position.
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope
Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu as a new growth engine and have raised their price target for RIGL, although execution risk for both products remains a key factor for investors to monitor. The fair value adjustment also reflects changes in revenue growth assumptions, net profit margin expectations, and future P/E multiples.
(RIGL) Price Dynamics and Execution-Aware Positioning
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific institutional trading strategies (Position, Momentum Breakout, and Risk Hedging). The analysis also provides multi-timeframe signal strengths and support/resistance levels for RIGL.
Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares of Rigel Pharmaceuticals (RIGL) common stock through a Schedule 13G/A filing. This represents 8.95% of the outstanding common stock as of June 30, 2026. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager, granting them shared voting and dispositive power over these securities.
RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85
HC Wainwright & Co. maintained a "Buy" rating for Rigel Pharmaceuticals (RIGL), increasing its price target from $57.00 to $85.00, reflecting confidence in the company's future growth. Despite this, Rigel Pharmaceuticals is currently priced at $42.10, which is 56.7% overvalued compared to its GF Value™ of $26.86, and insider activity shows net selling. The company's GF Score™ is 73/100, indicating fair financial health but notable weaknesses in profitability and valuation.
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals has announced the commercial availability of VEPPANU (vepdegestrant) in the United States. This drug is the first and only FDA-approved PROTAC and is indicated for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy. The company emphasizes VEPPANU's novel mechanism of action and its potential as an important new treatment option, supported by Rigel's existing oncology infrastructure and patient support programs.
Rigel Pharmaceuticals (RIGL): Soleus Capital group discloses 9.9% ownership stake
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 9.9% beneficial ownership stake in Rigel Pharmaceuticals, Inc. (RIGL). This ownership amounts to 1,843,504 shares of common stock, based on 18,679,864 shares outstanding as of July 30, 2026. The filing indicates shared voting and dispositive power over these shares among the Soleus entities and Guy Levy.
Rigel's VEPPANU Is Now Available for Certain Advanced Breast Cancers
Rigel Pharmaceuticals has announced the commercial availability of VEPPANU (vepdegestrant), an FDA-approved oral PROTAC, in the United States and Puerto Rico. This new treatment is for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. VEPPANU, priced at $29,400 per 30-day supply, is the first and only FDA-approved PROTAC and demonstrated significant progression-free survival improvement in clinical trials.
Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Rigel Pharmaceuticals (NASDAQ:RIGL) by 37.1% in the first quarter, now owning 379,541 shares valued at $10.3 million. This contributed to institutional investors holding 66.23% of the stock. Despite a "Strong Sell" downgrade from Zacks Research, analysts generally maintain a "Moderate Buy" rating with an average price target of $54.50, following Rigel's strong Q1 earnings beat with an EPS of $0.88 and revenue of $78.7 million.
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US), maintaining a target price of $57. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts
Rigel Pharmaceuticals (RIGL) saw its stock rally after its Q2 earnings release, with a 4.6% increase following a strong three-month run. The company maintained profitability with $17.3m in net income and $78.7m in total revenue, though revenue and EPS declined significantly year-over-year. While the company's existing products showed growth, concerns persist regarding the sustainability of its earnings due to reliance on one-time milestone payments and non-cash items, as well as significant future capital commitments.
Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts
Rigel Pharmaceuticals' stock rallied following its Q2 2026 earnings release, showing profitability with $17.3m net income and $78.7m total revenue, though cash declined. The article discusses both bullish points, highlighting growth from existing drugs and collaboration revenue, and bearish concerns about the quality of earnings, relying heavily on concentrated products and potentially non-recurring milestone income amidst new product commitments.
Rigel Pharmaceuticals Q2 2026 Earnings Call Transcript
Rigel Pharmaceuticals reported strong Q2 2026 results, with commercial revenue growing 14% year-over-year, driven by record TAVALISSE sales and REZLIDHIA growth. The company is accelerating the launch of VEPPANU, an FDA-approved breast cancer therapy, which it expects to be its largest future revenue driver, and is advancing its R289 development pipeline with top-line data expected by year-end. Rigel also raised its full-year 2026 total revenue guidance to $285 million-$295 million, excluding VEPPANU sales, and anticipates positive net income for the year.
Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RIGL)
Rigel Pharmaceuticals, Inc. (RIGL) published a slide deck in conjunction with their Q2 2026 earnings call. The company reported an EPS of $0.88, beating estimates by $0.96, and revenue of $78.70M, which also beat estimates by $23.43M despite a 22.60% year-over-year decrease. This article provides access to the earnings call presentation and related transcript and insights.
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Rigel Pharmaceuticals (RIGL) reported Q2 earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share, and significantly down from $3.28 per share a year ago. Despite missing EPS estimates, the company's Q2 revenues of $78.7 million surpassed the consensus estimate by 14.58%. Rigel's stock has underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #4 (Sell) due to an unfavorable estimate revisions trend.
(RIGL) as a Liquidity Pulse for Institutional Tactics
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models, highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies an exceptional short setup with a significant risk-reward ratio and outlines specific trading strategies for different risk profiles. The analysis includes multi-timeframe signal analysis and resistance/support levels for informed trading decisions.
Earnings Preview: RIGL to Report Financial Results Post-market on August 04
This article provides an earnings preview for RIGL, which is scheduled to report its financial results after market close on August 4th. Investors will be watching for key financial metrics and guidance.
Rigel Pharmaceuticals Inc (RIGL) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Rigel Pharmaceuticals Inc (RIGL), noting its current risk score of 4.47 and ranking it 86th out of 155 in the Pharmaceuticals industry. It highlights the company's beta of 1.19, indicating higher volatility compared to the S&P 500 index. The assessment details various metrics including VaR, maximum drawdown, volatility, and Sharpe ratio over different periods, offering insights into the stock's performance and associated risks.
Earnings Preview: RIGL to Report Financial Results Post-market on August 04
This article announces that Rigel Pharmaceuticals (RIGL) is scheduled to release its financial results after market close on August 4. The company will also host a webcast and conference call at 4:30 PM ET to discuss these results, which will be accessible for replay.
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The webcast will be accessible from the Investor Relations section of the company's website and will be archived for replay for 90 days.
Rigel Pharmaceuticals Inc (RIGL) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Rigel Pharmaceuticals Inc (RIGL), highlighting its current valuation score and P/E ratio. It notes that the company's P/E ratio is 1.90, significantly below its recent high and above its recent low. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by Rigel Pharmaceuticals Inc.
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Rigel Pharmaceuticals, Inc. will host a conference call and webcast on Tuesday, August 6, 2026, to discuss its second quarter 2026 financial results and provide a business update. The event will begin at 4:30 PM Eastern Time. Interested parties can access the call via phone or webcast, with an archived replay available for approximately one month.
Rigel schedules a live webcast for its Aug. 4 business update
Rigel Pharmaceuticals (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. A live conference call and webcast will follow at 4:30 p.m. ET, led by senior management, to discuss the results and provide a business update. Investors can access the event via phone or the Investor Relations section of Rigel's website, where a replay will be available for 90 days.
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will report its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. This will be followed by a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The webcast will be accessible from the Investor Relations section of the company's website and will be archived for replay.
RIGL|Rigel Pharmaceuticals Inc|Price:37.126|Chg%:-0.264
This article provides a comprehensive stock analysis of Rigel Pharmaceuticals Inc (RIGL) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways recently. The analysis also covers the company's valuation, institutional ownership, and analyst ratings, indicating a positive outlook for the stock in the medium term.
Rigel Pharmaceuticals Inc (RIGL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Rigel Pharmaceuticals Inc (RIGL), highlighting major institutional investors and their holdings. It breaks down shareholders by type and reports on changes in institutional ownership over several quarters. The data provides insights into which firms have significant stakes and how institutional investment in RIGL has evolved.
Rigel Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RIGL
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) generated $294.28 million in revenue last year, primarily from its Novel Therapies segment. This is an increase from $179.28 million the previous year. The United States was the company's largest contributor to revenue.
Rigel Pharmaceuticals Inc (RIGL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Rigel Pharmaceuticals Inc (RIGL). It indicates that the company has not distributed any dividends in the past five years. The report also details multiple merger-related stock splits with a 10:1 ratio that occurred on June 25, 2024.
Rigel Pharmaceuticals Inc (RIGL) Income Statement
This article provides the quarterly and annual income statements for Rigel Pharmaceuticals Inc (RIGL), offering detailed financial data such as total revenue, cost of revenue, operating expenses, and net income across multiple fiscal years and quarters. It also includes frequently asked questions about interpreting the income statement, key financial metrics, and recent performance figures for the company.
Rigel Pharmaceuticals, Inc. Revenue Breakdown – MUN:RI2
Rigel Pharmaceuticals, Inc. (MUN:RI2) generated 250.56 million EUR last year, a significant increase from 173.18 million EUR in the previous year. This revenue primarily stemmed from its Novel Therapies segment, with the United States being the largest contributing region. The company's financial performance highlights the continued growth of its core therapeutic area.
Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis
Rigel Pharmaceuticals Inc (RIGL) has a robust financial health score of 8.03, ranking 86th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a 10.28% year-over-year revenue increase to $58.82 million and a 24.39% year-over-year increase in net profit. While its financial status is strong, specific data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed.
(RIGL) Risk Channels and Responsive Allocation
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is presenting a weak near-term sentiment, although an exceptional 81.5:1 risk-reward setup is noted, targeting a 24.2% gain against 0.3% risk. AI models have developed three trading strategies: Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT), each with specific entry, target, and stop-loss levels. Multi-timeframe signal analysis reveals weak near-term sentiment and neutral mid-to long-term sentiments, along with corresponding support and resistance levels.
(RIGL) Risk Channels and Responsive Allocation
This article provides an AI-powered analysis of Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), highlighting strong near and mid-term sentiment, resistance testing, and an exceptional short setup. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report includes specific entry and target prices for various trading strategies and emphasizes real-time signals and risk management.
Rigel Pharmaceuticals (RIGL) Q1 2026 earnings summary
Rigel Pharmaceuticals (RIGL) announced total revenues of $58.8 million in Q1 2026, including $54.9 million in net product sales, marking a 26% year-over-year increase. The company maintained profitability with an $8.7 million net income despite higher R&D and SG&A expenses, driven by strong sales from TAVALISSE, GAVRETO, and REZLIDHIA. Rigel also reiterated its 2026 revenue guidance, expecting continued growth and profitability powered by an expanded commercial portfolio and advancing clinical pipeline.
Rigel Pharmaceuticals (RIGL) Corporate presentation Summary
Rigel Pharmaceuticals' corporate presentation outlines its transformational growth strategy, focusing on expanding its commercial business, advancing its pipeline, and in-licensing. The company has grown from one commercial product in 2020 to three by 2025, with a fourth, VEPPANU, expected in 2026, which is projected to be its largest revenue producer. Rigel achieved profitability in Q3 2024 and saw significant sales growth in Q1 2026 for its key products TAVALISSE, GAVRETO, and REZLIDHIA.
Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com
This article reports on a Form 4 filing by Rigel Pharmaceuticals Inc. for transactions that occurred on July 10th. The filing is a standard regulatory disclosure related to insider trading, though the article does not provide specific details from the form itself. The document simply serves as a notification of the filing's existence.
Rigel Pharmaceuticals (RIGL) CMO receives 24,400-share RSU equity award with 4-year vesting
Rigel Pharmaceuticals' EVP and Chief Medical Officer, Alison L. Hannah, was granted 24,400 Restricted Stock Units (RSUs) which will vest annually over four years, starting July 8, 2027. Following this award and the cancellation of 5,750 RSUs, Ms. Hannah directly holds 35,025 shares of common stock. This transaction was reported in a Form 4 filing, indicating an equity compensation event for the executive.
Rigel Pharmaceuticals (RIGL) Proxy filing Summary
Rigel Pharmaceuticals has issued a proxy filing summarized on April 3, 2026, outlining key proposals for its annual meeting scheduled for May 14, 2026. Shareholders will vote on the election of three directors, amendments to two equity incentive plans to add shares, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor. The Board of directors recommends voting in favor of all proposals and director nominees.
Rigel Pharmaceuticals (RIGL) Investor update Summary
Rigel Pharmaceuticals recently announced the exclusive global in-licensing of VEPPANU (vepdegestrant), an FDA-approved oral PROTAC for specific ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This strategic move is expected to make VEPPANU Rigel's largest commercial product and a major revenue driver, leveraging existing infrastructure. Clinical data from the VERITAC-2 trial demonstrated significant improvement in progression-free survival and a favorable safety profile for VEPPANU, which recently received FDA approval and NCCN Category 2A treatment option status in May 2026.
Rigel Pharmaceuticals (RIGL) Corporate presentation Summary
Rigel Pharmaceuticals (RIGL) presented a corporate summary highlighting its transformational growth strategy, achieving profitability since Q3 2024 and expanding to three commercial products in hematology and oncology. The company reported Q1 2026 net product sales of $54.9M, a 26% increase year-over-year, driven by products like TAVALISSE, GAVRETO, and REZLIDHIA. Rigel also detailed its pipeline, including the promising R289 in Phase 1b for relapsed/refractory lower-risk MDS, which has received Fast Track and Orphan Drug designations.
Rigel Pharmaceuticals, Inc. Announces Inducem
NULL
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. announced inducement grants to six non-executive employees under NASDAQ Listing Rule 5635(c)(4). These grants consist of 13,375 restricted stock units, vesting over four years at 25% annually. The awards are part of Rigel's Inducement Plan, approved by its Compensation Committee, to attract new talent.
Rigel awards new hires 13,375 RSUs under its inducement plan
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the grant of 13,375 restricted stock units (RSUs) to six new non-executive employees under its Inducement Plan. These awards, made in accordance with NASDAQ Listing Rule 5635(c)(4), will vest over four years, with 25% vesting annually. This move is aimed at attracting and retaining talent, and it resulted in a positive market reaction, with RIGL stock gaining 5.50%.
RI2 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Rigel Pharmaceuticals, Inc. (RI2) stock for 2027, including analyst price targets and ratings. It also offers key financial metrics such as EPS, revenue, net income, and EBITDA, along with historical stock performance and upcoming earnings dates. The content addresses frequently asked questions about the company's stock, trading information, and employee count.
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Rigel Pharmaceuticals, Inc. announced the appointment of Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer. Dr. Hannah, who previously served on Rigel's Board of Directors, brings extensive experience in oncology drug development. She will lead the advancement of Rigel's pipeline, including R289 for lower-risk MDS and vepdegestrant for metastatic breast cancer.
Press Release: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
This press release announces that Rigel Pharmaceuticals has appointed Dr. Alison L. Hannah as its new Chief Medical Officer, effective July 1, 2026. Dr. Hannah, who has been a member of Rigel's Board of Directors since 2019, brings extensive experience in drug development and medical affairs from her previous roles at Genentech/Roche. Rigel's CEO, Raul Rodriguez, expressed enthusiasm for her appointment, highlighting her strategic insights and commercial acumen as valuable assets for the company's future growth.
Alison Hannah joins Rigel (NASDAQ: RIGL) as new EVP and Chief Medical Officer
Rigel Pharmaceuticals (NASDAQ: RIGL) has appointed Alison L. Hannah, M.D. as its new Executive Vice President and Chief Medical Officer, effective July 1, 2026. Dr. Hannah, who previously served on Rigel's Board of Directors, resigned from the board upon her appointment to this executive role. Her appointment follows the departure of Lisa Rojkjaer, M.D., who ceased serving as EVP and CMO on June 25, 2026.
Rigel Pharmaceuticals Appoints Alison L. Hannah as Chief Medical Officer
Rigel Pharmaceuticals Inc. has appointed Alison L. Hannah, M.D., as its new executive vice president and chief medical officer, effective July 1. Hannah, who previously served on Rigel’s Board of Directors, brings extensive experience in oncology drug development and will lead the company's clinical programs. This appointment strengthens Rigel’s leadership as it advances its oncology and hematology pipeline, including the lead investigational candidate R289 and the recently added vepdegestrant program.
